WO2005113762A1 - Structure cristalline de proteine kinase b-$g(a) (akt-1) et utilisations correspondantes - Google Patents

Structure cristalline de proteine kinase b-$g(a) (akt-1) et utilisations correspondantes Download PDF

Info

Publication number
WO2005113762A1
WO2005113762A1 PCT/IB2005/001353 IB2005001353W WO2005113762A1 WO 2005113762 A1 WO2005113762 A1 WO 2005113762A1 IB 2005001353 W IB2005001353 W IB 2005001353W WO 2005113762 A1 WO2005113762 A1 WO 2005113762A1
Authority
WO
WIPO (PCT)
Prior art keywords
akt
amino acid
crystal
computer
coordinates
Prior art date
Application number
PCT/IB2005/001353
Other languages
English (en)
Inventor
Jayvardhan Pandit
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of WO2005113762A1 publication Critical patent/WO2005113762A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Definitions

  • the present invention relates to crystalline compositions of mammalian protein kinase B- ⁇ (Akt-1), methods of preparing said compositions, methods of determining the three-dimensional (3-D) X-ray atomic coordinates of said composition, methods of identifying ligands of Akt-1 using structure based drug design, the use of the 3-D crystal structure to design, modify and assess the activity of potential inhibitors, for the treatment of a variety of cancers, such as, for example breast, prostate, pancreas, lung and colorectal cancers.
  • Akt-1 mammalian protein kinase B- ⁇
  • Protein kinases control many of the intracellular processes that are dysregulated in human cancer, including the suppression of apoptosis and anoikis and the induction of cell cycle progression. (Zinda et ai, Clin Cancer Res. Aug; 7(8):2475-9 (2001)). Those skilled in the art will understand that this critical link between the intracellular signaling pathways and the regulating of cell cycle progression, morphology and the secretion of cellular proteins, such as for example growth hormones and chemokines, has lead to the emergence of protein kinases as a group of molecular targets with potential to be specific to cancer.
  • PKA Protein kinase B/Akts
  • PKA protein kinase A
  • PKC protein kinase C
  • SGK serum glucocorticoid stimulated kinase
  • S6 kinases Coffer and Woodgett, Eur. J. Biochem, 201 :475- 481 (1991); Jones et ai., Proc. Nat. Acad.
  • P13K phosphatidylinositol 3-kinase
  • P13K phosphatidylinositol 3-kinase
  • Pl(3,4)-P 2 phosphatidylinositol-(3,4,5)-triphosphate
  • Pl(3,4,5)-P 3 phosphatidylinositol 3-kinase
  • Akt-1 Akt-1
  • Akt-2 Akt-2
  • Akt-3 also known as PKB ⁇ , PKB ⁇ , and PKBv, respectively.
  • Akt-2 and Akt-3 show 81 % and 83% amino acid sequence identity, respectively, with Akt-1.
  • the Akt isoforms share a common domain organization that consists of a pleckstrin homology domain (PH domain) at the N-terminus, a kinase catalytic domain, and a short regulatory region at the C-terminus.
  • PH domain pleckstrin homology domain
  • Akt-1 appears to be the predominantly expressed isoform in most tissues, while Akt-2 is highly enriched in insulin target tissues.
  • the primary sequence of Akt-1 is well conserved between species, with greater than 90% identity between the amino acid sequences of chicken, mouse and human. (Kumar, et al. (2001)).
  • LDD ligand-directed drug discovery
  • QSAR quantitative structure activity relationship
  • CoMFA comparative molecular field analysis
  • CoMFA is a particular type of QSAR method that uses statistical correlation techniques for the analysis of the quantitative relationship between the biological activity of a set of compounds with a specified alignment, and their three-dimensional electronic and steric properties. Other properties such as hydrophobicity and hydrogen bonding can also be incorporated into the analysis.
  • An invaluable component of these drug discovery approaches is structure based design, which is a design strategy for new chemical entities, or optimization of lead compounds identified by other methods, using the three-dimensional (3D) structure of the biological macromolecule target obtained by for example, X-ray or nuclear magnetic resonance (NMR) studies, or from homology models. Analyzing 3-D structures of proteins provides crucial insights into the behavior and mechanics of drug binding and biological activity.
  • the present invention provides crystalline compositions of Akt-1, and specifically of the catalytic region of Akt-1.
  • the invention further provides methods of preparing compositions, methods of determining the 3-D X-ray atomic coordinates of the crystalline compositions, methods of using the atomic coordinates in conjunction with computational methods to identify binding site(s), methods to elucidate the 3-D structure of homologues of Akt-1 , and methods to identify ligands which interact with the binding site(s) to agonize or antagonize the biological activity of Akt-1 , methods for identifying inhibitors of Akt-1 , pharmaceutical compositions of inhibitors, and methods of treatment of cancer using said pharmaceutical compositions.
  • the invention provides crystalline compositions of the catalytic domain of the active form of Akt-1.
  • One aspect of the present invention provides methods for crystallizing an Akt-1 polypeptide.
  • the methods for crystallizing an Akt-1 polypeptide comprising an amino acid sequence spanning the amino acids 144 to 480 listed in SEQ ID NO:1 comprising the steps of: (a) preparing solutions of the polypeptide, ligand and precipitant; (b) growing a crystal comprising molecules of the polypeptide from the mixture solution; and (c) separating the crystal from the solution.
  • the crystallization growth can be carried out by various techniques known by those skilled in the art, such as for example, batch crystallization, liquid bridge crystallization, or dialysis crystallization.
  • the present invention is further intended to include such crystalligation growth techniques which serve equivalent functions and which become known in the area subsequently hereto.
  • the crystallization growth is achieved using vapor diffusion techniques.
  • the present invention provides vectors useful in methods for preparing a substantially purified C-terminal catalytic domain of Akt-1 comprising the polypeptide with an amino acid sequence spanning amino acids Arg144 to Ala480 listed in SEQ ID NO:1.
  • the present invention provides methods for determining the X-ray atomic coordinates of the crystalline compositions at a 2.02 A resolution.
  • the present invention provides a molecule or molecular complex crystal, wherein the crystal has substantially similar atomic coordinates to the atomic coordinates listed in FIG.4 or portions thereof, or any scalable variations thereof.
  • the present invention provides a molecule or molecular complex crystal, wherein the crystal comprises a polypeptide with an amino acid sequence spanning the amino acids Arg144 to Ala480 listed in SEQ ID NO:1.
  • a further embodiment of the invention provides a crystal comprising an amino acid sequence that is at least 98% homologous to a polypeptide with an amino acid sequence spanning the amino acids Arg144 to Ala480 listed in SEQ ID NO:1.
  • An even further embodiment of the invention provides a crystal comprising an amino acid sequence that is at least 95% homologous to a polypeptide with an amino acid sequence spanning the amino acids Arg144 to Ala480 listed in SEQ ID NO:1 , and which has the atomic coordinates listed in FIG. 4.
  • the present invention provides a molecule or molecular complex crystal, wherein the crystal comprises a polypeptide, or a portion thereof, with atomic coordinates having a root mean square deviation from the protein backbone atoms (N, C ⁇ , C, and O) listed in FIG.4 of less than 0.2, 0.5, 0.7, 1.0, 1.2, 1.5, 2.0 or 2.5 A.
  • the present invention provides a scalable, or translatable, three dimensional configuration of points derived from atomic coordinates of at least a portion of an Akt-1 molecule or molecular complex comprising a polypeptide with an amino acid sequence spanning the amino acids
  • the invention also comprises the structural coordinates of at least a portion of a molecule or a molecular complex that is structurally homologous to an Akt-1 molecule or molecular complex.
  • the configuration of points derived from a homologous molecule or molecular complex have a root mean square deviation of less than about 0.2, 0.5, 0.7, 1.0, 1.2, 1.5, 2.0 or 2.5 A. from the atomic coordinates provided in FIG. 4.
  • the present invention provides a computer for producing a three-dimensional representation of: a.
  • a molecule or molecular complex comprising a polypeptide with an amino acid sequence spanning amino acids Arg144 to Ala480 listed in SEQ ID NO:1, or a homologue, an analogue, or a variant thereof; b. a molecule or molecular complex, wherein the atoms of the molecule or molecular complex are represented by atomic coordinates that are substantially similar to, or are subsets of the atomic coordinates listed in FIG. 4; c.
  • a molecule or molecular complex wherein the molecule or molecular complex comprises atomic coordinates having a root mean square deviation of less than 0.2, 0.5, 0.7, 1.0, 1.2, 1.5, 2.0 or even 2.5 A from the atomic coordinates for the protein backbone atoms listed in FIG.4; or d. a molecule or molecular complex, wherein the molecule or molecular complex comprises a binding pocket or site defined by the structure coordinates that are substantially similar to the atomic coordinates listed in FIG. 4, or a subset thereof, or more preferably the structural coordinates in FIG.
  • said computer comprises: (i) a computer-readable data storage medium comprising a data storage medium encoded with computer-readable data, wherein said data comprises the structure coordinates of FIG.
  • a working memory for storing instructions for processing said computer-readable data
  • a central-processing unit coupled to said working memory and to said computer- readable data storage medium for processing said computer-machine readable data into said three- dimensional representation
  • a display coupled to said central-processing unit for displaying said representation.
  • the computer configured according to this aspect of the invention can be used to design and identify potential ligands or inhibitors of Akt-1 by, for example commercially available molecular modeling software in conjunction with structure-based drug design as provided herein.
  • the present invention provides methods involving molecular replacement to obtain structural information about a molecule or molecular complex of unknown structure.
  • the method includes crystallizing the molecule or molecular complex, generating an X-ray diffraction pattern from the crystallized molecule or molecular complex, and applying at least a portion of the structure coordinates set forth in FIG. 4 to the X-ray diffraction pattern to generate a three-dimensional electron density map of at least a portion of the molecule or molecular complex.
  • Another aspect of the present invention provides methods for generating 3-D atomic coordinates of a protein homoiogue, an analogue or a variant of Akt-1 using the X-ray coordinates of Akt-1 described in FIG. 4, comprising: a. identifying one or more homologous polypeptide sequences to Akt-1 ; b. aligning said sequences with the sequence of Akt-1 which comprises a polypeptide with an amino acid sequence spanning amino acids Arg144 to Ala480 listed in SEQ ID NO:1 ; c identifying structurally conserved and structurally variable regions between said homologous sequence(s) and Akt-1 ; d.
  • Embodiments of the ninth aspect provide methods which further comprise refining and evaluating the full or partial 3-D coordinates. These methods may thus be used for example to generate 3- dimensional structures for proteins for which 3-dimensional atomic coordinates have not been determined.
  • the present invention provides methods for identifying ligands, inhibitors, and the like, of Akt-1 by providing the coordinates of a molecule of Akt-1 to a computerized modeling system; identifying chemical entities that are likely to bind to the molecule (e.g., by screening a small molecule library); and, optionally, procuring or synthesizing and assaying the compounds or analogues derived for bioactivity.
  • a further aspect of the present invention relates to methods for identifying potential ligands for Akt-1 or homologues, an analogue or variants thereof comprising the steps of: a. displaying the three dimensional structure of Akt-1 enzyme or homoiogue, an analogue or variant thereof, or portions thereof, as defined by atomic coordinates that are substantially similar to the atomic coordinates listed in FIG. 4 on a computer display screen; b.
  • ligands include selective inhibitor of Akt-1.
  • the methods further comprise computationally modifying the structure of the ligand; computationally determining the fit of the modified ligand using the three-dimensional coordinates described in FIG. 4, or portions thereof; contacting said modified ligand with said enzyme, or homoiogue, an analogue or variant thereof in an in vitro or in vivo setting; and measuring the ability of said ligand to modulate the activity of said enzyme.
  • the present invention provides compositions, such as, pharmaceutical compositions designed according to any of the methods of the present invention.
  • a composition is provided that includes a selective inhibitor designed or identified by any of the above methods of the present invention.
  • the composition is a pharmaceutical composition.
  • the twelfth aspect of the present invention are methods for treating cancer comprising administering pharmaceutical compositions, identified by structure based design using the atomic coordinates, or portions thereof, listed in FIG. 4, effective in treating the tumors, of all stages, that over-express Akt-1 (e.g. breast, prostate, pancreas, lung, and colorectal cancers).
  • the present invention provides for a pharmaceutical composition comprising an inhibitor identified from the methods of the present invention and a pharmaceutically acceptable carrier, vehicle or diluent.
  • BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is an orthogonal view of the embodiment of the ternary complex of Akt-1 , GSK3- ⁇ peptide, and AMP-PNP.
  • Akt-1 and GSK3- ⁇ peptide are shown in ribbon representation and AMP-PNP is shown as a ball and stick figure. N- and C-termini of the polypeptide are labeled as well.
  • Figure 2 is another orthogonal view of the embodiment of the ternary complex.
  • Figure 3 is a schematic diagram showing the interactions of AMP-PNP with Akt-1.
  • Figure 4 is a list of the X-ray atomic coordinates of the active form of Akt-1 C-terminal catalytic domain crystal as described in the Examples.
  • the present invention relates to crystalline compositions of Akt-1 , 3-D X-ray atomic coordinates of said crystalline compositions, methods of preparing said compositions, methods of determining the 3-D X- ray atomic coordinates of said crystalline compositions, and methods of using said atomic coordinates in conjunction with computational methods to identify binding site(s), or identify ligands which interact with said binding site(s) to agonize or antagonize Akt-1.
  • certain terms employed in the specification, examples, and appendant claims are collected here. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the arts.
  • affinity refers to the tendency of a molecule to associate with another.
  • the affinity of a drug is its ability to bind to its biological target (receptor, enzyme, transport system, etc.).
  • affinity can be thought of as the frequency with which the drug, when brought into the proximity of a receptor by diffusion, will reside at a position of minimum free energy within the force field of that receptor.
  • agonist refers to a drug or compound that can interact with a receptor and initiate a physiological or a pharmacological response characteristic of that receptor (contraction, relaxation, secretion, enzyme activation, etc.).
  • analog refers to a drug or chemical compound whose structure is related in some way to that of another drug or chemical compound, but whose chemical and biological properties may be quite different.
  • antagonist refers to a drug or a compound that opposes the physiological effects of another. At the receptor level, it is a chemical entity that opposes the receptor- associated responses normally induced by another bioactive agent.
  • "Atomic coordinates”, “atomic structural coordinates”, “coordinates”, “structural coordinates", 3-D coordinates” or "X-ray coordinates” are the Cartesian coordinates corresponding to an atom's spatial relationship to other atoms in a molecule or molecular complex.
  • Structural coordinates may be obtained using X-ray crystallography techniques or NMR techniques, or may be derived using molecular replacement analysis or homology modeling.
  • Various software programs allow for the graphical representation of a set of structural coordinates to obtain a three dimensional representation of a molecule or molecular complex.
  • the structural coordinates of the present invention may be modified from the original sets provided in FIG. 4 by mathematical manipulation, such as by inversion or integer additions or subtractions. As such, it is recognized that the structural coordinates of the present invention are relative, and are in no way specifically limited by the actual x, y, z coordinates of FIG. 4.
  • binding site refers to a specific region (or atom) in a molecular entity that is capable of entering into a stabilizing interaction with another molecular entity. In certain embodiments the term also refers to the reactive parts of a macromolecule that directly participate in its specific combination with another molecule. In yet other embodiments, a binding site may be comprised or defined by the three dimensional arrangement of one or more amino acid residues within a folded polypeptide. In further embodiments, the binding site further comprises prosthetic groups, water molecules or metal ions which may interact with one or more amino acid residues. Prosthetic groups, water molecules, or metal ions may be apparent from X-ray crystallographic data, or may be added to an apo protein or enzyme using in silico methods.
  • bioactivity refers to Akt-1 activity that exhibits a biological property conventionally associated with an Akt-1 agonist or antagonist, such as a property that would allow treatment of one or more of the various diseases such as cancer.
  • catalytic domain refers to the catalytic domain of the Akt-1 class of enzymes, which features a conserved segment of amino acids in the carboxy-terminal portion of the proteins, wherein this segment has been demonstrated to include the catalytic site of these enzymes. This conserved catalytic domain extends approximately from residue Arg144 to Ala480 of the full-length enzyme (SEQ ID NO:1).
  • To clone as used herein, means obtaining exact copies of a given polynucleotide molecule using recombinant DNA technology. Furthermore, “to clone into” may be meant as inserting a given first polynucleotide sequence into a second polynucleotide sequence, preferably such that a functional unit combining the functions of the first and the second polynucleotides results. For example, without limitation, a polynucleotide from which a fusion protein may be translationally provided, which fusion protein comprises amino acid sequences encoded by the first and the second polynucleotide sequences.
  • the binding site may be defined for the purpose of structure based drug design as comprising only a handful of amino acid residues.
  • the ligand binding site can alternatively comprise at least about 80% of the amino acid residues selected from the group consisting of Val164, Ala177, Lys179, Glu228, Tyr229, Ala230, Lys276, Met281 and Thr291 of SEQ ID No:1.
  • the ligand binding site comprises at least about 90% of the amino acid residues selected from the group consisting of Val164, Ala177, Lys179, Glu228, Tyr229, Ala230, Lys276, Met281 and Thr291 of SEQ ID No:1.
  • any molecular assembly that has a root mean square deviation from the atomic structure coordinates of the protein backbone atoms (N, C ⁇ , C, and O), or the side chain atoms, of one or more of Val164, Ala177, Lys179, Glu228, Tyr229, Ala230, Lys276, Met281 and Thr291 of SEQ ID NO:1 , any conservative substitutions thereof, or any functional equivalence of less than about 2.5, 2.0, 1.5, 1.2, 1.0, 0.7, 0.5, or even 0.2 A when superimposed will be considered substantially similar to the coordinates listed in FIG.4.
  • the functional equivalents may be different from the peptides described herein at one, two, three, four, or more amino acid positions.
  • the terms “gene”, “recombinant gene” and “gene construct” refer to a nucleic acid comprising an open reading frame encoding a polypeptide, including both exon and (optionally) intron sequences.
  • the term “intron” refers to a DNA sequence present in a given gene which is not translated into protein and is generally found between exons.
  • the term “high affinity” as used herein means strong binding affinity between molecules with a dissociation constant K, of no greater than 1 mM. In a preferred case, the K, is less than 100 nM, 10 nM, 1 nM, 100 pM, or even 10 pM or less.
  • the two molecules can be covalently linked (K, is essentially 0).
  • the term "homoiogue” as used herein means a protein, polypeptide, oligopeptide, or portion thereof, having preferably at least 90% amino acid sequence identity with an Akt-1 enzyme as described in SEQ ID NO:1 or SEQ ID NO:2 or with any catalytic domain described herein, or with any functional or structural domain of lipid binding protein.
  • SEQ ID NO:1 is an amino acid sequence of a wild-type human Akt-1.
  • SEQ ID NO:2 is the amino acid sequence of the S473D mutant of the catalytic domain of human Akt-1 , that was crystallized in the Examples.
  • SEQ ID NO: 3 is the GSK3- ⁇ peptide used in the ternary complex. While SEQ ID NO:4 is the wild-type mus musculus (mouse) Akt-1 amino acid sequence, (Bellacosa, A., et al., Ongogene, Vol. 8: 745-754, 1993) SEQ ID NO:5 is the wild-type rattus norvegicus (rat) Akt-1 amino acid sequence (Konishi, H., et al., Biochem. Biophys. Res. Commun., Vol.
  • SEQ ID NO:6 is the wild-type bovine Akt-1 amino acid sequence, all are at least 90% identical with the Akt-1 enzyme as described in SEQ ID No:1 and, can also be used for crystallization and for the design and identification of potential ligands of Akt-1.
  • Akt-1 enzyme as described in SEQ ID No:1 and, can also be used for crystallization and for the design and identification of potential ligands of Akt-1.
  • the term "substantially similar atomic coordinates" or atomic coordinates that are “substantially similar” refers to any set of structure coordinates of Akt-1 or Akt-1 homologues, or Akt-1 variants, polypeptide fragments, described by atomic coordinates that have a root mean square deviation for the atomic coordinates of protein backbone atoms (N, C ⁇ , C, and O) of less than about 2.5, 2.0, 1.5, 1.2, 1.0, 0.7, 0.5, or even 0.2 A when superimposed using backbone atoms of the structure coordinates listed in FIG. 4. Structures that have substantially similar coordinates as those listed in FIG. 4 shall be considered identical to the coordinates listed in FIG. 4.
  • substantially similar also applies to an assembly of amino acid residues that may or may not form a contiguous polypeptide chain, but whose three dimensional arrangement of atomic coordinates have a root mean square deviation for the atomic coordinates of protein backbone atoms (N, C ⁇ , C, and O), or the side chain atoms, of less than about 2.5, 2.0,1.5, 1.2, 1.0, 0.7, 0.5, or even 0.2 A when superimposed using backbone atoms, or the side chain atoms of the atomic coordinates of similar or the same amino acids from the coordinates listed in FIG. 4.
  • Those skilled in the art understand that "substantially similar" atomic coordinates are considered identical to the coordinates, or portions thereof, listed in FIG. 4.
  • the coordinates listed in FIG. 4 or portions thereof may be transformed into a different set of coordinates using various mathematical algorithms without departing from the present invention.
  • the coordinates listed in Fig. 4, or portions thereof may be transformed by algorithms which translate or rotate the atomic coordinates.
  • molecular mechanics, molecular dynamics or ab intio algorithms may modify the atomic coordinates.
  • Atomic coordinates generated from the coordinates listed in FIG. 4, or portions thereof, using any of the aforementioned algorithms shall be considered identical to the coordinates listed in FIG. 4.
  • the term "in silico" as used herein refers to experiments carried out using computer simulations.
  • the in silico methods are molecular modeling methods wherein 3-dimensional models of macromolecules or ligands are generated.
  • the in silico methods comprise computationally assessing ligand binding interactions.
  • ligand describes any molecule, e.g., protein, peptide, peptidomimetics, oligopeptide, small organic molecule, polysaccharide, polynucleotide, etc., which binds or interacts, generally but not necessarily specifically to or with another molecule. More particularly, a ligand can further be defined as any molecule which is designed or developed with reference to the crystal structure of Akt-1 as represented by the atomic coordinates listed in FIG. 4.
  • the ligand is an agonist, whereby the molecule upregulates (i.e., activate or stimulate, e.g., by agonizing or potentiating) activity, while in another aspect of the invention the ligand is an inhibitor or antagonist, whereby the molecule down- regulates (i.e., inhibit or suppress, e.g. by antagonizing, decreasing or inhibiting) the activity.
  • modulate refers to both upregulation (i.e., activation or stimulation, e.g., by agonizing or potentiating) and down-regulation (i.e., inhibition or suppression, e.g., by antagonizing, decreasing or inhibiting) of an activity.
  • pharmacophore refers to the ensemble of steric and electronic features of a particular structure that is necessary to ensure the optimal supramolecular interactions with a specific biological target structure and to trigger (or to block) its biological response.
  • a pharmacophore is an abstract concept that accounts for the common molecular interaction capacities of a group of compounds towards their target structure.
  • the term can be considered as the largest common denominator shared by a set of active molecules.
  • Pharmacophoric descriptors are used to define a pharmacophore, including H-bonding, hydrophobic and electrostatic interaction sites, defined by atoms, ring centers and virtual points.
  • a pharmacophore may represent an ensemble of steric and electronic factors which are necessary to insure supramolecular interactions with a specific biological target structure.
  • a pharmacophore may represent a template of chemical properties for an active site of a protein/enzyme representing these properties' spatial relationship to one another that theoretically defines a ligand that would bind to that site.
  • the term "precipitant” as used herein is includes any substance that, when added to a solution, causes a precipitate to form or crystals to grow.
  • Suitable precipitants include, but are not limited to, alkali (e.g., Li, Na, or K), or alkaline earth metal (e.g., Mg, or Ca) salts, and transition metal (e.g., Mn, or Zn) salts.
  • Common counterions to the metal ions include, but are not limited to, halides, phosphates, citrates and sulfates.
  • prodrug refers to drugs that, once administered, are chemically modified by metabolic processes in order to become pharmaceutically active. In certain embodiments the term also refers to any compound that undergoes biotransformation before exhibiting its pharmacological effects.
  • Prodrugs can thus be viewed as drugs containing specialized non-toxic protective groups used in a transient manner to alter or to eliminate properties, usually undesireable, in the parent molecule.
  • the term "receptor” as used here in refers to a protein or a protein complex in or on a cell that specifically recognizes and binds to a compound acting as a molecular messenger (neurotransmitter, hormone, lymphokine, lectin, drug, etc.). In a broader sense, the term receptor is used interchangeably with any specific (as opposed to non-specific, such as binding to plasma proteins) drug binding site, also including nucleic acids such as DNA.
  • recombinant protein refers to a polypeptide which is produced by recombinant DNA techniques, wherein generally, DNA encoding a polypeptide is inserted into a suitable expression vector which is, in turn, used to transform a host cell to produce the polypeptide encoded by the DNA.
  • This polypeptide may be one that is naturally expressed by the host cell, or it may be heterologous to the host cell, or the host cell may have been engineered to have lost the capability to express the polypeptide which is otherwise expressed in wild type forms of the host cell.
  • the polypeptide may also be, for example, a fusion polypeptide.
  • Akt-1 inhibitor refers to a substance, such as for example, an organic molecule, that effectively inhibits an enzyme from the Akt-1 family to a greater extent than any other Akt enzyme, particularly any enzyme from the PKB/Akt family.
  • a selective Akt-1 inhibitor is a substance having a Kj for inhibition of Akt-1 that is less than about one-half, one-fifth, or one- tenth the K
  • the substance inhibits Akt-1 activity to the same degree at a concentration of about one-half, one-fifth, one- tenth or less than the concentration required for any other PKB/Akt enzyme.
  • a substance is considered to effectively inhibit Akt-1 if it has an IC 5 o or K
  • small molecules refers to preferred drugs as they are orally available (unlike proteins which must be administered by injection or topically).
  • the size of the small molecules is generally under 1000 Daltons, but many estimates seem to range between 300 to 700 Daltons.
  • space group refers to a group or array of operations consistent with an infinitely extended regularly repeating pattern. It is the symmetry of a three-dimensional structure, or the arrangement of symmetry elements of a crystal. There are 230 space group symmetries possible; however, there are only 65 space group symmetries available for biological structures.
  • substantially portion of atomic coordinates refers to a plurality of at least twelve atomic coordinates that define or partially define the location of several atoms in the binding protein or ligand. Preferably, a substantial portion is at least 24 coordinates. More preferably, a substantial portion is at least 36 coordinates. The coordinates can be within the standard deviation.
  • therapeutically effective amount is meant that amount which is capable of preventing the progression of the disease, e.g., cancer, treating the disease, or at least partially reversing the symptoms of the disease.
  • a therapeutically effective amount can be determined on an individual basis, and will be based, at least in part, on a consideration of the species of the mammal, the size of the mammal, the type of delivery system used, and the type of administration relative to the progression of the disease.
  • transfection means the introduction of a nucleic acid, e.g., via an expression vector, into a recipient cell by nucleic acid mediated gene transfer.
  • Transformation refers to a process in which a cell's genotype is changed as a result of the cellular uptake of exogenous DNA or RNA and, for example, the transformed cell expresses a recombinant form of a polypeptide or, in the case of anti-sense expression from the transferred gene, the expression of a naturally-occurring form of the polypeptide is disrupted.
  • unit cell refers to a basic parallelepiped shaped block. The entire volume of a crystal may be constructed by regular assembly of such blocks. Each unit cell comprises a complete representation of the unit of pattern, the repetition of which builds up the crystal.
  • variants in relation to the polypeptide sequence in SEQ ID NO:1 or SEQ ID NO:2 include any substitution of, variation of, modification of, replacement of, deletion of, or addition of one or more amino acids from or to the sequence providing a resultant polypeptide sequence for an enzyme having AKT-1 activity.
  • the variant, homoiogue, fragment or portion, of SEQ ID NO:1 , or SEQ ID NO:2 comprises a polypeptide sequence of at least 5 contiguous amino acids, preferably at least 10 contiguous amino acids, preferably at least 15 contiguous amino acids, preferably at least 20 contiguous amino acids, preferably at least 25 contiguous amino acids, or preferably at least 30 contiguous amino acids.
  • vector refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
  • One type of preferred vector is an episome, i.e., a nucleic acid capable of extra- chromosomal replication.
  • Preferred vectors are those capable of autonomous replication and/or expression of nucleic acids to which they are linked.
  • Vectors capable of directing the expression of genes to which they are operatively linked are referred to herein as "expression vectors”.
  • expression vectors of utility in recombinant DNA techniques are often in the form of "plasmids" which refer generally to circular double stranded DNA loops which, in their vector form are not bound to the chromosome.
  • plasmid and "vector” are used interchangeably as the plasmid is the most commonly used form of vector.
  • vector is intended to include such other forms of expression vectors which serve equivalent functions and which become known in the art subsequently hereto.
  • nucleotide sequence coding for an Akt-1 polypeptide, or functional fragment, including the C-terminal peptide fragment of the catalytic domain of Akt-1 protein, derivatives or analogs thereof, including a chimeric protein, thereof can be inserted into a suitable expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence.
  • a suitable expression vector i.e., a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence.
  • the nucleic acid encoding a Akt-1 polypeptide of the invention or a functional fragment comprising the C-terminal peptide fragment of the catalytic domain of Akt-1 protein, derivatives or analogs thereof is operationally associated with a promoter in an expression vector of the invention.
  • the expression vector contains the nucleotide sequence coding for the polypeptide comprising the amino acid sequence spanning amino acids Arg144 to Ala480 listed in SEQ ID NO:1. Both cDNA and genomic sequences can be cloned and expressed under the control of such regulatory sequences.
  • An expression vector also preferably includes a replication origin. The necessary transcriptional and translational signals can be provided on a recombinant expression vector. As detailed below, all genetic manipulations described for the Akt-1 gene in this section, may also be employed for genes encoding a functional fragment, including the C-terminal peptide fragment of the catalytic domain of the Akt-1 protein, derivatives or analogs thereof, including a chimeric protein thereof.
  • Suitable host-vector systems include, but are not limited to, mammalian cell systems infected with virus (e.g., vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g., baculovirus); microorganisms such as yeast containing yeast vectors; or bacteria transformed with bacteriophage, DNA, plasmid DNA, or cosmid DNA.
  • virus e.g., vaccinia virus, adenovirus, etc.
  • insect cell systems infected with virus e.g., baculovirus
  • microorganisms such as yeast containing yeast vectors
  • bacteria transformed with bacteriophage DNA, plasmid DNA, or cosmid DNA.
  • the expression elements of vectors vary in their strengths and specificities. As those of skill in the art can appreciate, depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may be used.
  • any of a number of amplification systems may be used to achieve high levels of stable gene expression.
  • a suitable cell for purposes of this invention is one into which the recombinant vector comprising the nucleic acid encoding Akt-1 protein is cultured in an appropriate cell culture medium under conditions that provide for expression of Akt-1 protein by the cell.
  • Any of the methods previously described for the insertion of DNA fragments into a cloning vector may be used to construct expression vectors containing a gene consisting of appropriate transcriptional/translational control signals and the protein coding sequences. These methods may include in vitro recombinant DNA and synthetic techniques, and in vivo recombination (genetic recombination).
  • Akt-1 protein may be controlled by any promoter/enhancer element known in the art, provided that these regulatory elements must be functional in the host selected for expression, as would be appreciated by those skilled in the art.
  • Vectors containing a nucleic acid encoding an Akt-1 protein of the invention can be identified for example by four general approaches: (1) PCR amplification of the desired plasmid DNA or specific mRNA; (2) nucleic acid hybridization; (3) presence or absence of selection marker gene functions; and (4) expression of inserted sequences.
  • the invention is intended to include such other forms of identification of vectors containing a nucleic acid encoding an Akt-1 protein of the present invention, which serve equivalent functions and which become known in the art subsequently hereto.
  • the nucleic acids can be amplified by PCR to provide for detection of the amplified product.
  • the presence of a foreign gene inserted in an expression vector can be detected by nucleic acid hybridization using probes comprising sequences that are homologous to an inserted marker gene.
  • the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "selection marker" gene functions (e.g., beta-galactosidase activity, thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of foreign genes in the vector.
  • selection marker e.g., beta-galactosidase activity, thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.
  • recombinant vectors containing the Akt-1 protein insert can be identified by the absence of the Akt-1 protein gene function.
  • recombinant expression vectors can be identified by assaying for the activity, biochemical, or immunological characteristics of the gene product expressed by the recombinant vector, provided that the expressed protein assumes a functionally active conformation.
  • host/expression vector combinations may be employed in expressing the DNA sequences of this invention as known by those of skill in the art. Once a particular recombinant DNA molecule is identified and isolated, several methods known in the art may be used to propagate it.
  • the expression vectors which can be used include, but are not limited to, the following vectors or their derivatives: human or animal viruses such as vaccinia virus or adenovirus; insect viruses such as baculovirus; yeast vectors; bacteriophage vectors (e.g., lambda), and plasmid and cosmid DNA vectors, to name but a few.
  • Vectors can be introduced into the desired host cells by methods known in the art, e.g., transfection, electroporation, microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, lipofection (lysosome fusion), use of a gene gun, or a DNA vector transporter (see, e.g., Wu et ai., 1992, J. Biol. Chem. 267:963-967; Wu and Wu, 1988, J. Biol. Chem. 263:14621-14624; Hartmut et al., Canadian Patent Application No. 2,012,311 , filed Mar. 15, 1990).
  • X-ray structure coordinates define a unique configuration of points in space.
  • a set of structure coordinates for a protein or a protein/ligand complex, or a portion thereof define a relative set of points that, in turn, define a configuration in three dimensions.
  • a similar or identical configuration can be defined by an entirely different set of coordinates, provided the distances and angles between atomic coordinates remain essentially the same.
  • a scalable configuration of points can be defined by increasing or decreasing the distances between coordinates by a scalar factor while keeping the angles essentially the same.
  • One aspect of the present invention relates to a crystalline composition
  • a crystalline composition comprising preferably a polypeptide with an amino acid sequence spanning amino acids Arg144 to Ala480 listed in SEQ ID NO:1.
  • the present invention discloses a crystalline Akt-1 molecule comprising a polypeptide with an amino acid sequence spanning amino acids Arg144 to Ala480 listed in SEQ ID NO:1 complexed with one or more ligands.
  • the crystallized complex is characterized by the structural coordinates listed in FIG. 4, or portions thereof.
  • the atoms of the ligand are within about 4, 7, or 10 angstroms of one or more Akt-1 amino acids in SEQ ID NO: 1 preferably selected from Val164, Ala1 7, Lys179, Glu228, Tyr229, Ala230, Lys276, Met281 and Thr291.
  • the ligand may be a small molecule which binds to an Akt-1 catalytic domain defined by SEQ ID NO: 2, or portions thereof, with a K, of less than about 10 ⁇ M, 1 ⁇ M, 500 nM, 100 nM, 50 nM, or 10 nM.
  • the ligand is a substrate or substrate analog of Akt-1.
  • the ligand(s) may be a competitive or uncompetitive inhibitor of Akt-1.
  • the ligand is a covalent inhibitor of Akt-1.
  • Various computational methods can be used to determine whether a molecule or a binding pocket portion thereof is "structurally equivalent,” defined in terms of its three-dimensional structure, to all or part of Akt-1 or its binding pocket(s). Such methods may be carried out in current software applications, such as the molecular similarity application of QUANTA (Accelrys Inc., San Diego, Calif.).
  • the molecular similarity application permits comparisons between different structures, different conformations of the same structure, and different parts of the same structure.
  • the procedure used in molecular similarity to compare structures is divided into four steps: (1) load the structures to be compared; (2) optionally define the atom equivalences in these structures; (3) perform a fitting operation; and (4) analyze the results. Each structure is identified by a name.
  • One structure is identified as the target (i.e., the fixed structure), while all remaining structures are working structures (i.e., moving structures). Since atom equivalency within molecular similarity applications is defined by user input, for the purpose of this invention equivalent atoms are defined as protein backbone atoms (N, C ⁇ , C, and O) for all conserved residues between the two structures being compared. A conserved residue is defined as a residue that is structurally or functionally equivalent (See Table 4 infra). In further embodiments rigid fitting operations are considered. In other embodiments, flexible fitting operations may be considered. When a rigid fitting method is used, the working structure is translated and rotated to obtain an optimum fit with the target structure.
  • the fitting operation uses an algorithm that computes the optimum translation and rotation to be applied to the moving structure, such that the root mean square difference of the fit over the specified pairs of equivalent atoms is an absolute minimum. This number, given in angstroms (A), is reported by the molecular similarity application. Any molecule or molecular complex or binding pocket thereof, or any portion thereof, that has a root mean square deviation of conserved residue backbone atoms (N, C ⁇ , C, and O) of less than about 2.5, 2.0, 1.5 A, 1.0 A, 0.7 A, 0.5 A or even 0.2 A, when superimposed on the relevant backbone atoms described by the reference structure coordinates listed in FIG. 4, is considered "structurally equivalent" to the reference molecule.
  • N, C ⁇ , C, and O conserved residue backbone atoms
  • the crystal structures of those portions of the two molecules are substantially identical, within acceptable error.
  • Particularly preferred structurally equivalent molecules or molecular complexes are those that are defined by the entire set of structural coordinates listed in FIG. 4, plus or minus a root mean square deviation from the conserved backbone atoms of those amino acids of not more than 2.5 A. More preferably, the root mean square deviation is less than about 1.0 A.
  • the term "root mean square deviation” means the square root of the arithmetic mean of the squares of the deviations. It is a way to express the deviation or variation from a trend or object.
  • the "root mean square deviation” defines the variation in the backbone of a protein from the backbone of Akt-1 or a binding pocket portion thereof, as defined by the structural coordinates of Akt-1 described herein.
  • the refined X-ray atomic coordinates of the catalytic domain of Akt-1 (amino acids 144 to 480 as listed in SEQ ID NO:1 ), co-crystallized with the non-hyrolyzable ATP analog AMP-PNP and a substrate peptide, preferably GSK3- ⁇ , residues 3-12, as shown in SEQ ID NO: 3, 2 Mn 2+ ions and 76 water molecules are as listed in FIG. 4.
  • the protein adopts a typical bilobate "kinase-fold", with two alpha-helices ( ⁇ B and ⁇ C, following the naming convention established for PKA-REF, (Knighton, D.R., et al., Science, Vol. 253:407-414, 1991)) and a beta-sheet in the N-terminal lobe (N-lobe) and an all alpha-helical C-terminal lobe (C-lobe).
  • the ⁇ C helix adopts the same conformation as seen in other active protein kinases
  • AMP-PNP binds in the cleft between the N- and C-terminal lobes of Akt-1 , with a pair of conserved hydrogen bonds formed between the adenine base and the backbone of the kinase linker region.
  • the bound peptides appear to help anchor the gamma phosphate of ATP to the enzyme.
  • the present invention provides a molecule or molecular complex that includes at least a portion of an Akt-1 and/or substrate binding pocket.
  • the Akt-1 binding pocket includes the amino acids listed in Table 1 , preferably the amino acids listed in Table 2, and more preferably the amino acids listed in Table 3, the binding pocket being defined by a set of points having a root mean square deviation of less than about 2.5, 2.0, 1.5, 1.2, 1.0, 0.7, 0.5, or even 0.2 A, from points representing the backbone atoms of the amino acids in Tables 1-3.
  • the Akt-1 substrate binding pocket includes the amino acids selected from VaI164, Ala177, Lys179, Glu228, Tyr229, Ala230, Lys276, Met281 and Thr291 of SEQ ID NO:1.
  • Table 1 Residues near the binding pocket in Akt-1 catalytic domain. Identified residues are 10 A away from the non-hydrolyzable ATP analog, AMP-PNP.
  • Table 2 Residues near the binding pocket in Akt-1 catalytic domain. Identified residues are 7 A away from the non-hydrolyzable ATP analog, AMP-PNP.
  • Table 3 Residues near the binding pocket in Akt-1 catalytic domain. Identified residues are 4 A away from the non-hydrolyzable ATP analog, AMP-PNP.
  • One embodiment of the invention describes an isolated polypeptide consisting of a portion of Akt- 1 which functions as the binding site when folded in the proper 3-D orientation.
  • One embodiment is an isolated polypeptide comprising a portion of Akt-1 , wherein the portion starts at about amino acid residue Arg144, and ends at about amino acid residue Ala480 as described in SEQ ID NO:1, or a sequence that is at least 95% or 98% homologous to a polypeptide with an amino acid sequence spanning amino acids Arg144 to Ala480 as listed in SEQ ID NO:1 , such as, for example the polypeptide of the wild-type mus musculus (mouse), SEQ ID NO:4, the wild-type rattus norvegicus (rat) Akt-1 amino acid sequence SEQ ID NO:5, and wild-type bovine Akt-1 amino acid sequence, SEQ ID NO:6.
  • variants of Akt-1 may have an amino acid sequence that is different by one or more amino acid substitutions to the sequence disclosed in SEQ ID NO:1 or SED ID NO:2.
  • Embodiments which comprise amino acid deletions and/or additions are also provided.
  • the variant may for example have conservative changes (amino acid similarity), wherein a substituted amino acid has similar structural or chemical properties, for example, the replacement of leucine with isoleucine.
  • Negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; amino acids, with uncharged polar head groups having similar hydrophiiicity values include leucine, isoleucine, and valine; amino acids with aliphatic head groups include glycine, alanine; asparagine, glutamine, serine; and amino acids with aromatic side chains include threonine, phenylalanine, and tyrosine. Examples of conservative substitutions are set forth in Table 4 as follows: Table 4:
  • “Homology” is a measure of the identity of nucleotide sequences or amino acid sequences. To characterize the homology, subject sequences are aligned so that the highest percentage homology (match) is obtained, after introducing gaps, if necessary, to achieve maximum percent homology. N- or C- terminal extensions shall not be construed as affecting homology. "Identity" per se has an art-recognized meaning and can be calculated using published techniques. Computer program methods to determine identity between two sequences, for example, include DNAStar® software; the GCG® program package (Devereux, J., et al. Nucleic Acids Research (1984) 12(1): 387); BLASTP, BLASTN, FASTA (Atschul, S.F.
  • the parameters are set such that the percentage of identity is calculated over the full length of the reference nucleotide sequence or amino acid sequence and that gaps in homology of up to about 95% of the total number of nucleotides in the reference sequence are allowed.
  • Similarity between two sequences includes direct matches as well a conserved amino acid substitutes which possess similar structural or chemical properties, e.g., similar charge as described in Table 4. Percentage similarity (conservative substitutions) between two polypeptides may also be scored by comparing the amino acid sequences of the two polypeptides by using programs well known in the art, including the BESTFIT program, by employing default settings for determining similarity.
  • a further embodiment of the invention is a crystal comprising the coordinates of FIG.4, wherein the amino acid sequence is represented by SEQ ID NO:1.
  • a further embodiment of the invention is a crystal comprising the coordinates of FIG. 4, wherein the amino acid sequence is at least 95% or 98% homologous to the amino acid sequence represented by SEQ ID NO:1.
  • Various methods for obtaining atomic coordinates of structurally homologous molecules and molecular complexes using homology modeling are disclosed in, for example, US Patent No. 6,356,845.
  • a test compound (antagonist or agonist) may be examined through the use of computer modeling using a docking program such as GRAM, DOCK, or AUTODOCK (See for example, Morris et al., J. Computational Chemistry, 19:1639-1662 (1998)).
  • This procedure can include in silico fitting of potential ligands to the Akt-1 crystal structure to ascertain how well the shape and the chemical structure of the potential ligand will complement or interfere with the catalytic domain of Akt-1.
  • One embodiment of the present invention relates to methods of identifying agents that bind to a binding site on Akt-1 's catalytic domain, wherein the binding site comprises amino acid residues Val164, Ala177, Lys179, Glu228, Tyr229, Ala230, Lys276, Met281 and Thr291 , of SEQ ID NO:1 , comprising: contacting Akt-1 with a test compound under conditions suitable for binding of the test compound to the binding site, and determining whether the test compound binds in the binding site, wherein if binding occurs, the test ligand is an agent that binds in the binding site.
  • the testing may be carried out in silico using a variety of molecular modeling software algorithms including, but not limited to, DOCK, ALADDIN, CHARMM simulations, AFFINITY, C2-LIGAND FIT, Catalyst, LUDI, CAVEAT, and CONCORD.
  • molecular modeling software algorithms including, but not limited to, DOCK, ALADDIN, CHARMM simulations, AFFINITY, C2-LIGAND FIT, Catalyst, LUDI, CAVEAT, and CONCORD.
  • a potential ligand may be obtained by screening a random peptide library produced by a recombinant bacteriophage (Scott and Smith, Science, 249:386-390 (1990); Cwirla et al., Proc. Natl. Acad. Sci., 87:6378-6382 (1990); Devlin et al., Science, 249:404-406 (1990)) or a chemical library, or the like.
  • a ligand selected in this manner can be then be systematically modified by computer modeling programs until one or more promising potential ligands are identified.
  • Such analysis for example, has been shown to be effective in the development of HIV protease inhibitors.
  • a potential ligand (agonist or antagonist)
  • it can be either selected from a library of chemicals as are commercially available from most large chemical companies or alternatively the potential ligand may be synthesized de novo. As mentioned above, the de novo synthesis of one or even a relatively small group of specific compounds is reasonable in the art of drug design.
  • the potential ligand can be placed into any standard binding assay as well known to those skilled in the art to test its effect on Akt-1 activity.
  • another crystal can be grown comprising a protein-ligand complex formed between an Akt-1 protein and the drug.
  • the crystal diffracts X-rays allowing the determination of the atomic coordinates of the protein-ligand complex to a resolution of less than 5.0 Angstroms, more preferably less than 3.0 Angstroms, and even more preferably less than 2.0 Angstroms.
  • the three-dimensional structure of the supplemental crystal can be determined by Molecular Replacement Analysis. Molecular replacement involves using a known three-dimensional structure as a search model to determine the structure of a closely related molecule or protein-ligand complex in a new crystal form.
  • the measured X-ray diffraction properties of the new crystal are compared with the search model structure to compute the position and orientation of the protein in the new crystal.
  • Computer programs that can be used include: X-PLOR and AMORE (J. Navaza, Acta Crystallographies ASO, 157- 163 (1994)).
  • X-PLOR and AMORE J. Navaza, Acta Crystallographies ASO, 157- 163 (1994)
  • an electron density map can be calculated using the search model to provide X-ray phases. Thereafter, the electron density is inspected for structural differences, and the search model is modified to conform to the new structure.
  • claimed structure of Akt-1 can be used to solve the three-dimensional structures of any such Akt-1 complexed with a new ligand.
  • STAT crystals include: QUANTA; CHARMM; INSIGHT; SYBYL; MACROMODEL; and ICM.
  • Suitable in silico methods for screening, designing or selecting ligands are disclosed in, for example, US Patent No. 6,356,845.
  • the present invention provides ligands which interact with a binding site of the Akt- 1 catalytic domain defined by a set of points having a root mean square deviation of less than about 2.5 A from points representing the backbone atoms of the amino acids represented by the structure coordinates listed in FIG.4.
  • a further embodiment of the present invention comprises binding agents which interact with a binding site of Akt-1 defined by a set of points having a root mean square deviation of less than about 2.5, 2.0, 1.7, 1.5, 1.2, 1.0, 0.7, 0.5, or even 0.2 A from points representing the backbone atoms of the amino acids represented by the structure coordinates listed in FIG. 4.
  • Such embodiments represent variants of the Akt-1 crystal.
  • the present invention provides ligands which bind to a correctly folded polypeptide comprising an amino acid sequence spanning amino acids 144 to 480 listed in SEQ ID NO:1 , or a homoiogue or variant thereof.
  • the ligand is a competitive or uncompetitive inhibitor of Akt-1.
  • the ligand inhibits Akt-1 with an IC 50 or Ki of less than about 10 yM, 1 ⁇ M, 500nM, 100nM, 50nM, 10nM or even 1 nM.
  • the ligand inhibits Akt-1 with a K, that is less than about one-half, one-fifth, or one-tenth the Ki that the substance has for inhibition of any other Akt enzyme. More specifically, the substance inhibits Akt-1 activity to the same degree at a concentration of about one-half, one-fifth, one-tenth or less than the concentration required for any other Akt enzyme.
  • ligands such as proteins, peptides, peptidomimetics, small organic molecules, etc., designed or developed with reference to the crystal structure of Akt-1 as represented by the coordinates presented herein in FIG. 4, and portions thereof.
  • Such binding agents interact with the binding site of the Akt-1 represented by one or more amino acid residues selected from Val164, Ala177, Lys179, GIu228, Tyr229, Ala230, Lys276, Met281 and Thr291.
  • the machine-readable data storage medium comprises a data storage material encoded with machine readable data which, when using a machine programmed with instructions for using said data, is capable of displaying a graphical three-dimensional representation of a molecule or molecular complex comprising all or any parts of a Akt-1 C-terminal catalytic domain or binding pocket, as defined above.
  • the machine-readable data storage medium is capable of displaying a graphical three-dimensional representation of a molecule or molecular complex defined by the structure coordinates of the amino acids listed in FIG. 4, plus or minus a root mean square deviation from the backbone atoms of said amino acids of not more than 2.5 A.
  • the machine-readable data storage medium comprises a data storage material encoded with a first set of machine readable data which comprises the Fourier transform of the structural coordinates set forth in FIG. 4, and which, when using a machine programmed with instructions for using said data, can be combined with a second set of machine readable data comprising the X-ray diffraction pattern of a molecule or molecular complex to determine at least a portion of the structural coordinates corresponding to the second set of machine readable data.
  • a system for reading a data storage medium may include a computer comprising a central processing unit (“CPU"), a working memory which may be, e.g., RAM (random access memory) or “core” memory, mass storage memory (such as one or more disk drives or CD-ROM drives), one or more display devices (e.g., cathode-ray tube (“CRT”) displays, light emitting diode (“LED”) displays, liquid crystal displays (“LCDs”), electroluminescent displays, vacuum fluorescent displays, field emission displays (“FEDs”), plasma displays, projection panels, etc.), one or more user input devices (e.g., keyboards, microphones, mice, touch screens, etc.), one or more input lines, and one or more output lines, all of which are interconnected by a conventional bidirectional system bus.
  • CPU central processing unit
  • working memory which may be, e.g., RAM (random access memory) or “core” memory, mass storage memory (such as one or more disk drives or CD-ROM drives), one or more display devices (e
  • the system may be a stand-alone computer, or may be networked (e.g., through local area networks, wide area networks, intranets, extranets, or the internet) to other systems (e.g., computers, hosts, servers, etc.).
  • the system may also include additional computer controlled devices such as consumer electronics and appliances.
  • Input hardware may be coupled to the computer by input lines and may be implemented in a variety of ways. Machine-readable data of this invention may be inputted via the use of a modem or modems connected by a telephone line or dedicated data line. Alternatively or additionally, the input hardware may comprise CD-ROM drives or disk drives. In conjunction with a display terminal, a keyboard may also be used as an input device.
  • Output hardware may be coupled to the computer by output lines and may similarly be implemented by conventional devices.
  • the output hardware may include a display device for displaying a graphical representation of a binding pocket of this invention using a program such as QUANTA as described herein.
  • Output hardware might also include a printer, so that hard copy output may be produced, or a disk drive, to store system output for later use.
  • a CPU coordinates the use of the various input and output devices, coordinates data accesses from mass storage devices, accesses to and from working memory, and determines the sequence of data processing steps.
  • a number of programs may be used to process the machine-readable data of this invention. Such programs are discussed in reference to the computational methods of drug discovery as described herein.
  • Machine-readable storage devices useful in the present invention include, but are not limited to, magnetic devices, electrical devices, optical devices, and combinations thereof.
  • Examples of such data storage devices include, but are not limited to, hard disk devices, CD devices, digital video disk devices, floppy disk devices, removable hard disk devices, magneto-optic disk devices, magnetic tape devices, flash memory devices, bubble memory devices, holographic storage devices, and any other mass storage peripheral device.
  • these storage devices include necessary hardware (e.g., drives, controllers, power supplies, etc.) as well as any necessary media (e.g., disks, flash cards, etc.) to enable the storage of data.
  • necessary hardware e.g., drives, controllers, power supplies, etc.
  • any necessary media e.g., disks, flash cards, etc.
  • compositions The present invention provides methods for treating certain diseases in a mammal, preferably a human beings, in need of such treatment using the ligands, and preferably the inhibitors, as described herein.
  • the ligand can be advantageously formulated into pharmaceutical compositions comprising a therapeutically effective amount of the ligand, a pharmaceutically acceptable carrier and other compatible ingredients, such as adjuvants, Freund's complete or incomplete adjuvant, suitable for formulating such pharmaceutical compositions as is known to those skilled in the art.
  • Pharmaceutical compositions containing the ligand can be used for the treatment of a a variety of cancers, such as, for example breast, prostate, colon and lung.
  • the pharmaceutical composition is administered to the mammal in a therapeutically effective amount such that treatment of the disease occurs.
  • the present invention is further illustrated by the following examples, which should not be construed as limiting in any way.
  • the contents of all cited references (including literature references, issued patents, published patent applications as cited throughout this application) are hereby expressly incorporated by reference in their entireties.
  • Akt1 S473D
  • pFastbac Hta The DNA fragment encoding residues 144-480 of human Akt-1 (SEQ ID NO:1) was amplified by PCR using the following primers: (1 ) Akt1 -R144F (5'-AATATGGATCCGCGCGTGACCATGAACGAG-3'), which introduces a Bam HI site at the N-terminus, and (2) (2) Akt1-A480R (5'- AATTC CGAGTTATCAGGCCGTGCTGCTGGCCGAGTAGG-3'), which introduces a Xho I site at the C-terminus.
  • the high-fidelity PCR core reagent kit (Stratagene, La Jolla, CA, USA) and the PTC-200 DNA Engine (96- well format; MJ Research, Watertown, MA, USA) were used for PCR using the following protocol: 1 cycle of 2 min at 92°C and then 35 cycles of 40 s at 92°C, 50 s at 55°C, 2 min at 68°C.
  • the PCR product (1014 bp) was column (Roche Applied Sciences) purified, digested with BamYW and Xho ⁇ restriction enzymes and sub- cloned into the pFastbac HTa baculovirus transfer vector (Gibco BRL), according to manufacturer's protocol (Gibco BRL).
  • Akt-1 Site-specific substitution of Akt-1 : Ser 473 to Asp (S473D) was performed using a QuickChange XL Site-Directed mutation kit (Stratagene) as described by the manufacturer, and resulted in the A473D human Akt mutant construct.
  • the final construct that encodes the hAkt-1 , (residues 144-480 and S473D), in pFastbac HTa is referred to as Akt1 -Construct #7. Oligonucleotides were synthesized by Invitrogen Life Technologies (Frederick, MD).
  • E. coli clones with recombinant bacmid were obtained after transformation of E. coli DHIOBac cells (Invitrogen Corp.) with 5 ng of Akt1 -Construct #7 plasmid DNA and blue/white-screening according to manufacturer's protocol (Invitrogen).
  • Monolayers of Sf ⁇ cells (20 X 10 6 cells in a 162 cm 2 culture flask) were transfected by overlaying 20 ml of transfection mixture containing 100 ⁇ l of mini-prep bacmid DNA and 100 ⁇ l of CellFECTIN reagent (Gibco BRL) in Sf-900 II Serum Free Medium (SFM). The transfection mixture was removed after 5 h of incubation (27 S C) and the cells were overlaid with 25 ml of Sf-900 II SFM.
  • the recombinant virus (P0) were harvested at 72h post-transfection, and further amplification of the virus was achieved by infecting 1 L of Sf-9 cells (1.2 X 10 6 cells/ml) with 20 ml of the P0 virus for 65-72 h.
  • Baculo Infected Insect Cells (BMC) stocks were prepared as follows: when the cell diameter increased by 2-4 ⁇ m above the baseline (usually 65-72h) and while the cell viability was > 80%, the BIIC's were gently spun down and re-suspended in a freezing medium (90% SF900 II, 1% w/v BSA, 10% v/v DMSO) at 1 X 10 7 viable cells/ml.
  • Akt-1 Construct Quickly thaw one vial (1 ml) of BIIC in a 37°C water bath and transfer the cell suspension to 100 ml of SF900 II media (1 :100 dilution). A 3L erienmeyer flask containing 1 L of Sf9 cells (1.2 X 10 6 cells/ml) in SF900 II media was infected with 10 ml of 1 :100 diluted BIIC cell suspension.
  • Example 2 Purification of Akt-1 wild type catalytic domain Baculovirus cell paste, from a 10L cell culture, containing the overexpressed Akt-1 recombinant protein was resuspended in 3 volumes (3.0ml_/g) Buffer A (50mM Tris pH 7.5, 300mM NaCl (sodium chloride), 0.5mM TCEP (Tri(2-carboxyethyl) phosphine hydrochloride)) and CompleteTM protease inhibitor cocktail tablets (Roche). The cells were lysed with one pass on a microfluidizer and the cell debris was removed by centrifugation at 4°C for 35 minutes at 14,000 rpm in a Sorval SLA-1500 rotor.
  • Buffer A 50mM Tris pH 7.5, 300mM NaCl (sodium chloride), 0.5mM TCEP (Tri(2-carboxyethyl) phosphine hydrochloride)
  • TCEP Tri(2-carbox
  • the supernatant was transferred to a clean tube and 10ml of TALON Metal Affinity Resin (BD-Clonetech) was added. The suspension was incubated with gentle rocking at 4°C for 1 hour and then subjected to centrifugation at 700 x g in a swinging bucket rotor. The supernatant was discarded and the resin was resuspended in 20ml Buffer A and transferred to an XK-16 column (Amersham Biosciences (UK)) connected to an FPLCTM. The resin was washed with 10 column volumes of Buffer A, or until, absorption reading at a wavelength of 280 was ⁇ 0.1.
  • TALON Metal Affinity Resin BD-Clonetech
  • the column containing the bound resin was connected upstream to a XK-26/30 Fast Desalt column (Pharmacia) previously equilibrated with Buffer A.
  • the Akt-1 was eluted from the TALON resin with a step gradient of Buffer A pius120mM Imidizole (pH 7.5).
  • the eluted fractions were pooled and directly loaded onto a HiPrep 26/10 desalting column (Amersham Biotech), which was previously equilibrated with Buffer B (25mM Tris pH 7.5, 200mM NaCl, 0.5mM TCEP (tri(2-carboxyethyl) phosphine hydrochloride).
  • the eluted fractions were digested with 2000U rTEV protease (Invitrogen Frederick, MD) overnight at 17°C. Completeness of cleavage was checked using SDS-Page or LC/MS.
  • the digested Akt- 1 protein was loaded onto a TALON column, which was equilibrated with Buffer B. The flow through fractions were collected, pooled and concentrated using Vivaspin-20, 10K MWCO at 4°C. The concentrated fractions where next loaded onto a Superdex 75 HiLoad 16/60 prep grade column (Pharmacia) equilibrated with Buffer C (25mM Tris pH 7.5, 150mM NaCl, and 1mM TCEP).
  • Example 3 Activation of Akt-1 with (PDK-1) PDK1 -active his-myc protein was added to the purified Akt-1 recombinant protein from Example 2, at a ratio of 1.0mgPDk/30.0mg Akt-1. (PDK-1 was produced by recombinant expression in an insect cell system using standard cloning and purification procedures known in the art).
  • 1.0 M of MgCI 2 was added making a final concentration of 5.0 mM, and 0.1M ATP was also added to a final concentration of 1.0 mm in Buffer C (25 mM Tris pH 7.5, 150 mM Na and 1.0 mM TCEP) forming a reaction.
  • Buffer C 25 mM Tris pH 7.5, 150 mM Na and 1.0 mM TCEP
  • the reaction was incubated reaction at room temperature for 90 minutes, thereafter loaded reaction onto a 1.0 mL HiTrap Heparin HP column (Amersham Biotech) equilibrated with Buffer C. Collected the flow through fractions. Performed a buffer exchange on the flow through fractions into Buffer C using a HiPrep 26/10 desalting column (Amersham Biotech) to remove ATP.
  • Example 4 Crystallization of the ternary complex of Akt-1 wild-type catalytic domain with AMP-
  • Crystallization screens were setup using the sitting drop/vapor diffusion method in 96-well Greiner plates.
  • a mixture of activated Akt-1 protein was pre-incubated for 1 hour at a concentration of 2 mg/ml with the following mixture: 10OmM MnCI 2 (manganese chloride) to a final concentration of 2.5mM; 2mM of the substrate peptide GSK3- ⁇ to a final concentration of 0.3mM; and 20mM AMP-PNP to a final concentration of 2.5mM.
  • the protein mixture sample was at a final concentration of 5-6 mg/ml.
  • the protein mixture was next combined (at a ratio of 1 :1) with the precipitate containing 20% PEG 10K (polyethylene glycol-10,000), and 0.1 M HEPES (4-(2-hydroxyethyl)-1 -piperazineethanesulfonic acid) pH 7.5.
  • PEG 10K polyethylene glycol-10,000
  • HEPES 4-(2-hydroxyethyl)-1 -piperazineethanesulfonic acid
  • Example 5 X-ray data collection, structure determination and refinement of active Akt-1 :AMP- PNP:GSK3- ⁇ complex
  • the crystals prepared in Example 4 were transferred to a cryoprotectant solution, made up of the reservoir solution, with 15% ethylene glycol, and then flash-frozen in a stream of cold nitrogen gas at 100K.
  • X-ray diffraction data were collected on a Rigaku HTC detector, mounted on a Rigaku FR-E X-ray generator operated at 45kV, 45mA. Data were processed using the d * trek suite of software (Molecular Structure Corporation), and data collection statistics are summarized in Table 5a.
  • the structure was solved by the method of molecular replacement, using the program AmoRe (Navaza, J., (1994). Ada Cryst A ⁇ O 157-163).
  • a homology model of Akt-1 was used as the starting search model.
  • the final model was built with a combination of automatic fitting in the program arpWarp (http://www. arp-warp.orq) , and manual rebuilding on the graphics screen using the program O.
  • the final refined model contains 318 out of 342 amino acid residues of the Akt1 protein construct. Clear electron density is seen for the substrate peptide, AMP-PNP and two putative Mn 2+ ions. Table 5a -Data statistics

Abstract

Cette invention concerne la structure cristalline de la protéine kinase B (Akt-1), et ses utilisations pour identifier des ligands de Akt-1, notamment des composés inhibiteurs de Akt-1.
PCT/IB2005/001353 2004-05-18 2005-05-06 Structure cristalline de proteine kinase b-$g(a) (akt-1) et utilisations correspondantes WO2005113762A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57230404P 2004-05-18 2004-05-18
US60/572,304 2004-05-18

Publications (1)

Publication Number Publication Date
WO2005113762A1 true WO2005113762A1 (fr) 2005-12-01

Family

ID=34967097

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/001353 WO2005113762A1 (fr) 2004-05-18 2005-05-06 Structure cristalline de proteine kinase b-$g(a) (akt-1) et utilisations correspondantes

Country Status (1)

Country Link
WO (1) WO2005113762A1 (fr)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354944B2 (en) 2004-10-18 2008-04-08 Amgen Inc. Thiadiazole compounds and methods of use
WO2006094230A3 (fr) * 2005-03-03 2009-04-09 Burnham Inst Medical Research Procedes d'analyse pour la detection d'inhibiteurs de proteine kinase b reposant sur des approches de fixation virtuelles, et composes et compositions mis au jour par ces procedes
WO2009158376A1 (fr) * 2008-06-26 2009-12-30 Smithkline Beecham Corporation Inhibiteurs d’activité akt
WO2009158374A3 (fr) * 2008-06-26 2010-02-18 Glaxosmithkline Llc Inhibiteurs d’activité akt
WO2010045309A1 (fr) * 2008-10-16 2010-04-22 Glaxosmithkline Llc Inhibiteurs de l’activité akt
WO2010075443A1 (fr) * 2008-12-22 2010-07-01 Burnham Institute For Medical Research Inhibiteurs sélectifs d'akt et leurs procédés d'utilisation
US7897619B2 (en) 2007-07-17 2011-03-01 Amgen Inc. Heterocyclic modulators of PKB
EP2399909A1 (fr) 2006-07-06 2011-12-28 Array Biopharma, Inc. Cyclopenta[d]pyrimidines hydroxylées et méthoxylées utilisées en tant qu'inhibiteurs de la protéine kinase akt
EP2404907A1 (fr) 2007-07-05 2012-01-11 Array Biopharma, Inc. Pyrimidyl cyclopentanes en tant qu'inhibiteurs de protéine kinase AKT
WO2012158197A2 (fr) * 2010-11-11 2012-11-22 Lyndor Biosciences L.L.C. Composés utiles en tant que modulateurs akt/pkb et leurs utilisations
US8324221B2 (en) 2008-01-09 2012-12-04 Array Biopharma Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US8329709B2 (en) 2008-01-09 2012-12-11 Genentech, Inc. 5H-cyclopenta[D]pyrimidines as AKT protein kinase inhibitors
WO2013009869A2 (fr) 2011-07-11 2013-01-17 Integrated Diagnostics, Inc. Agents de capture spécifiques de akt, compositions et leurs procédés d'utilisation et de fabrication
WO2013056015A1 (fr) 2011-10-14 2013-04-18 Incyte Corporation Dérivés d'isoindolinone et de pyrrolopyridinone en tant qu'inhibiteurs d'akt
WO2013078254A1 (fr) 2011-11-22 2013-05-30 Array Biopharma Inc. Dérivés hétéroaryles bicycliques en tant qu'inhibiteurs de kinase
US8618097B2 (en) 2007-07-05 2013-12-31 Array Biopharma, Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
WO2014130923A2 (fr) 2013-02-25 2014-08-28 Genentech, Inc. Procédés et compositions pour détecter et traiter un mutant d'akt résistant aux médicaments
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US11719705B2 (en) 2017-06-15 2023-08-08 Indi Molecular, Inc. IL-17F and IL-17A-specific capture agents, compositions, and methods of using and making
US11723944B2 (en) 2015-03-16 2023-08-15 Indi Molecular, Inc. Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making
US11733246B2 (en) 2020-11-03 2023-08-22 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (FOLR1)
US11884707B2 (en) 2016-09-29 2024-01-30 Regeneron Pharmaceuticals, Inc. Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) and methods of making and using same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003016516A2 (fr) * 2001-08-14 2003-02-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Structures cristallines de kinases et materiaux et procedes d'activation de kinases
WO2003016517A2 (fr) * 2001-08-14 2003-02-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Structures cristallines de kinase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003016516A2 (fr) * 2001-08-14 2003-02-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Structures cristallines de kinases et materiaux et procedes d'activation de kinases
WO2003016517A2 (fr) * 2001-08-14 2003-02-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Structures cristallines de kinase

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CASTILLO S SIANNA ET AL: "Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues", CANCER RESEARCH, vol. 64, no. 8, 15 April 2004 (2004-04-15), pages 2782 - 2792, XP002339661, ISSN: 0008-5472 *
HUANG XIN ET AL: "Crystal structure of an inactive Akt2 kinase domain.", STRUCTURE (CAMBRIDGE), vol. 11, no. 1, January 2003 (2003-01-01), pages 21 - 30, XP002339658, ISSN: 0969-2126 *
MEUILLET EMMANUELLE J ET AL: "Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxy-phosphatidyl-myo-inositol analogues.", MOLECULAR CANCER THERAPEUTICS, vol. 2, no. 4, April 2003 (2003-04-01), pages 389 - 399, XP002339689, ISSN: 1535-7163 *
MILBURN CHRISTINE C ET AL: "Binding of phosphatidylinositol 3,4,5-trisphosphate to the pleckstrin homology domain of protein kinase B induces a conformational change.", BIOCHEMICAL JOURNAL, vol. 375, no. 3, 1 November 2003 (2003-11-01), pages 531 - 538, XP002339659, ISSN: 0264-6021 *
YANG J ET AL: "CRYSTAL STRUCTURE OF AN ACTIVATED AKT/PROTEIN KINASE B TERNARY COMPLEX WITH GSK3-PEPTIDE AND AMP-PNP", NATURE STRUCTURAL BIOLOGY, NEW YORK, NY, US, vol. 9, no. 12, December 2002 (2002-12-01), pages 940 - 944, XP008015207, ISSN: 1072-8368 *
YANG JING ET AL: "Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation", MOLECULAR CELL, vol. 9, no. 6, June 2002 (2002-06-01), pages 1227 - 1240, XP002339657, ISSN: 1097-2765 *

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700636B2 (en) 2004-10-18 2010-04-20 Amgen Inc. Thiadiazole compounds and methods of use
US7354944B2 (en) 2004-10-18 2008-04-08 Amgen Inc. Thiadiazole compounds and methods of use
US7919514B2 (en) 2004-10-18 2011-04-05 Amgen Inc. Thiadiazole compounds and methods of use
WO2006094230A3 (fr) * 2005-03-03 2009-04-09 Burnham Inst Medical Research Procedes d'analyse pour la detection d'inhibiteurs de proteine kinase b reposant sur des approches de fixation virtuelles, et composes et compositions mis au jour par ces procedes
EP2966065A2 (fr) 2006-07-06 2016-01-13 Array Biopharma, Inc. Pyrimidines cyclopenta [d] hydroxylées et méthoxylées utilisées en tant qu'inhibiteurs de la protéine kinase akt
EP2399909A1 (fr) 2006-07-06 2011-12-28 Array Biopharma, Inc. Cyclopenta[d]pyrimidines hydroxylées et méthoxylées utilisées en tant qu'inhibiteurs de la protéine kinase akt
EP2402325A2 (fr) 2006-07-06 2012-01-04 Array Biopharma, Inc. Cyclopenta[d]pyrimidines hydroxylées et méthoxylées utilisées en tant qu'inhibiteurs de la protéine kinase AKT
EP2404907A1 (fr) 2007-07-05 2012-01-11 Array Biopharma, Inc. Pyrimidyl cyclopentanes en tant qu'inhibiteurs de protéine kinase AKT
US8618097B2 (en) 2007-07-05 2013-12-31 Array Biopharma, Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US7897619B2 (en) 2007-07-17 2011-03-01 Amgen Inc. Heterocyclic modulators of PKB
US9346805B2 (en) 2008-01-09 2016-05-24 Array Biopharma Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US8324221B2 (en) 2008-01-09 2012-12-04 Array Biopharma Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US8329709B2 (en) 2008-01-09 2012-12-11 Genentech, Inc. 5H-cyclopenta[D]pyrimidines as AKT protein kinase inhibitors
US8895566B2 (en) 2008-01-09 2014-11-25 Array Biopharma Inc. 5H-cyclopenta[d]pyrimidines as AKT protein kinase inhibitors
US9328091B2 (en) 2008-01-09 2016-05-03 Genentech, Inc. 5H-cyclopenta[d]pyrimidines as AKT protein kinase inhibitors
WO2009158374A3 (fr) * 2008-06-26 2010-02-18 Glaxosmithkline Llc Inhibiteurs d’activité akt
WO2009158376A1 (fr) * 2008-06-26 2009-12-30 Smithkline Beecham Corporation Inhibiteurs d’activité akt
WO2010045309A1 (fr) * 2008-10-16 2010-04-22 Glaxosmithkline Llc Inhibiteurs de l’activité akt
US8592475B2 (en) 2008-10-16 2013-11-26 Glaxosmithkline Llc Inhibitors of Akt activity
WO2010075443A1 (fr) * 2008-12-22 2010-07-01 Burnham Institute For Medical Research Inhibiteurs sélectifs d'akt et leurs procédés d'utilisation
WO2012158197A3 (fr) * 2010-11-11 2013-03-14 Lyndor Biosciences L.L.C. Composés utiles en tant que modulateurs akt/pkb et leurs utilisations
WO2012158197A2 (fr) * 2010-11-11 2012-11-22 Lyndor Biosciences L.L.C. Composés utiles en tant que modulateurs akt/pkb et leurs utilisations
EP2732291A4 (fr) * 2011-07-11 2015-07-29 Indi Molecular Inc Agents de capture spécifiques de akt, compositions et leurs procédés d'utilisation et de fabrication
US10221214B2 (en) 2011-07-11 2019-03-05 Indi Molecular, Inc. Akt-specific capture agents, compositions, and methods of using and making
US9239332B2 (en) 2011-07-11 2016-01-19 Indi Molecular, Inc. Akt-specific capture agents, compositions, and methods of using and making
WO2013009869A2 (fr) 2011-07-11 2013-01-17 Integrated Diagnostics, Inc. Agents de capture spécifiques de akt, compositions et leurs procédés d'utilisation et de fabrication
US8895571B2 (en) 2011-10-14 2014-11-25 Incyte Corporation Isoindolinone and pyrrolopyridinone derivatives as Akt inhibitors
WO2013056015A1 (fr) 2011-10-14 2013-04-18 Incyte Corporation Dérivés d'isoindolinone et de pyrrolopyridinone en tant qu'inhibiteurs d'akt
WO2013078254A1 (fr) 2011-11-22 2013-05-30 Array Biopharma Inc. Dérivés hétéroaryles bicycliques en tant qu'inhibiteurs de kinase
WO2014130923A2 (fr) 2013-02-25 2014-08-28 Genentech, Inc. Procédés et compositions pour détecter et traiter un mutant d'akt résistant aux médicaments
US11723944B2 (en) 2015-03-16 2023-08-15 Indi Molecular, Inc. Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making
US11884707B2 (en) 2016-09-29 2024-01-30 Regeneron Pharmaceuticals, Inc. Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) and methods of making and using same
US11719705B2 (en) 2017-06-15 2023-08-08 Indi Molecular, Inc. IL-17F and IL-17A-specific capture agents, compositions, and methods of using and making
US11733246B2 (en) 2020-11-03 2023-08-22 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (FOLR1)

Similar Documents

Publication Publication Date Title
WO2005113762A1 (fr) Structure cristalline de proteine kinase b-$g(a) (akt-1) et utilisations correspondantes
Ho et al. Brain acetylhydrolase that inactivates platelet-activating factor is a G-protein-like trimer
US20050075795A1 (en) Crystal structure of 3', 5'-cyclic nucleotide phosphodiesterase (PDE1B) and uses thereof
US20050202550A1 (en) Crystal structure of 3', 5'-cyclic nucleotide phosphodiesterase (PDE10A) and uses thereof
Tang et al. Structure of the Rtt109-AcCoA/Vps75 complex and implications for chaperone-mediated histone acetylation
WO2005119526A1 (fr) Structure cristalline de dipeptidyl peptidase iv (dpp-iv) et ses utilisations
US20040171019A1 (en) PIN1 peptidyl-prolyl isomerase polypeptides, their crystal structures, and use thereof for drug design
EP1243596A2 (fr) Domaines catalytiques du recepteur humain de facteur de croissance hepatocyte et procédés pour identifier inhibiteurs de cela
WO2005083069A1 (fr) Structures cristallines de type pde2 pour la conception de medicaments sur le plan structurel
US6921653B2 (en) Crystalline UDP-glycosyl transferase (MurG) and methods of use thereof
WO1999057253A2 (fr) Complexes de jnk cristallisables
US20070032403A1 (en) Crystal structure of the ITK kinase domain
Komolov et al. Atomic structure of G protein-coupled receptor kinase 5 (GRK5) reveals distinct structural features novel for GRKs
AU781654B2 (en) Crystallization and structure determination of staphylococcus aureus thymidylate kinase
US20090317850A1 (en) Crystal Structure of Human 70KD Ribosomal Protein S6 Kinase 1 Kinase Domain
US6689595B1 (en) Crystallization and structure determination of Staphylococcus aureus thymidylate kinase
JP2005525785A (ja) キナーゼ結晶構造
WO2005119525A1 (fr) Structures cristallines de 11?hsd1 utilisees pour la conception de medicaments
US7776589B1 (en) Polynucleotides encoding polypeptide fragments of protein kinase B gamma (AKT3)
WO2005103241A1 (fr) Structure cristalline de 3'-5'-phosphodiesterase nucleotidique cyclique 9a (pde9a) et ses utilisations
US20040171074A1 (en) Structures of substrate binding pockets of SCF complexes
JP2006521791A (ja) プロテインキナーゼＣθの触媒ドメインの立体構造、その方法および使用
MXPA06009940A (en) Crystal structure of 3',5'-cyclic nucleotide phosphodiesterase (pde10a) and uses thereof
US20060234293A1 (en) Polypeptide methods and means
EP1157101A1 (fr) Conception de medicaments bases sur la structure de la lta 4?-hydrolase

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase